USPTO Patent Grant for Bispecific Antibodies

The USPTO has granted a patent (US12577314B2) to ABL BIO INC. for bispecific antibodies designed to treat diseases related to BCMA and/or 4-1BB proteins. The patent covers the antibody's structure and its therapeutic applications.

US Patent 12577313B2 for Bispecific Antibodies

The USPTO has granted US Patent 12577313B2 for bispecific antibodies targeting claudin 18.2 and 4-1BB, assigned to I-Mab Biopharma US Limited. The patent covers novel antibody designs that can trigger tumor-specific immune responses.

Anti-CSF1R Antibodies and Pharmaceutical Compositions Patent

The USPTO has granted patent US12577309B2 for anti-CSF1R antibodies, pharmaceutical compositions, and their uses. The patent was assigned to DRAGONBOAT BIOPHARMACEUTICAL (SHANGHAI) CO., LTD. and lists six inventors. The patent's abstract describes antibodies against human CSF-1R.

USPTO Grants Patent for PI3K-α Inhibitors to Relay Therapeutics

The USPTO has granted a patent (US12581252B2) to Relay Therapeutics, Inc. for substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors. The patent covers novel compounds and pharmaceutical compositions for treating disorders associated with PI3Kα signaling.

USPTO Patent Granted for HER4 Antibodies

The USPTO has granted patent US12577324B2 to INSERM for antibodies with specificity to HER4 and their uses. The patent covers fully human anti-HER4 single-chain variable antibody fragments (scFv) that bind to an epitope of the HER4 protein.

USPTO Patent Grant for GRP78 Antibodies in Cancer Treatment

The USPTO has granted a patent (US12577301B2) to Rutgers, The State University of New Jersey for GRP78-binding antibodies. These antibodies are intended for the detection, diagnosis, and therapeutic treatment of cancers.

USPTO Patent Grant for Anti-IL-27 Antibodies

The USPTO has granted patent US12577299B2 to Surface Oncology, LLC for anti-IL-27 antibodies and their use in treating diseases, including cancer. The patent covers methods for administering these antibodies within specific dosage ranges.

Juno Therapeutics Engineered T Cell Production Patent

The USPTO has granted Juno Therapeutics, Inc. a patent (US12577285B2) for a process to produce engineered T cells for cell therapy. The patent covers methods for pooling and stimulating T cells, introducing genetic material, and cultivating them for therapeutic use.

PURE LOKA Cancellation Proceeding Filed

The USPTO's Trademark Trial and Appeal Board (TTAB) has filed a new cancellation proceeding, TTAB92091199, concerning the mark PURE LOKA. The proceeding was initiated by We Are Loka Limited against Crystal McClendon.

USPTO TTAB Cancellation: PENANGO

The USPTO's Trademark Trial and Appeal Board (TTAB) has initiated a cancellation proceeding for the trademark PENANGO. Peningo Systems, Inc. is the plaintiff, and Penango, Inc. is the defendant. The filing date for this cancellation was March 20, 2026.